Rn. Channick et al., Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study, LANCET, 358(9288), 2001, pp. 1119-1123
Citations number
31
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background Endothelin 1, a powerful endogenous vasoconstrictor and mitogen,
might be a cause of pulmonary hypertension. We describe the efficacy and s
afety of bosentan, a dual endothelin-receptor antagonist that can be taken
orally, in patients with severe pulmonary hypertension.
Methods In this double-blind, placebo-controlled study, 32 patients with pu
lmonary hypertension (primary or associated with scleroderma) were randomly
assigned to bosentan (62.5 mg taken twice daily for 4 weeks then 125 mg tw
ice daily) or placebo for a minimum of 12 weeks. The primary endpoint was c
hange in exercise capacity. Secondary endpoints included changes in cardiop
ulmonary haemodynamics, Borg dyspnoea index, WHO functional class, and with
drawal due to clinical worsening. Analysis was by intention to treat.
Findings In patients given bosentan, the distance walked in 6 min improved
by 70 m at 12 weeks compared with baseline, whereas it worsened by 6 m in t
hose on placebo (difference 76 m [95% Cl 12-139], p = 0.021). The improveme
nt was maintained for at least 20 weeks. The cardiac index was 1.0 L min(-1
) m(-2) (95% Cl 0.6-1.4, p < 0.0001) greater in patients given bosentan tha
n in those given placebo. Pulmonary vascular resistance decreased by 223 dy
n s cm(-5) with bosentan, but increased by 191 dyn s cm(-5) with placebo (d
ifference -415 [-608 to -221], p = 0.0002). Patients given bosentan had a r
educed Borg dyspnoea index and an improved WHO functional class. All three
withdrawals from clinical worsening were in the placebo group (p = 0.033).
The number and nature of adverse events did not differ between the two grou
ps.
Interpretation Bosentan increases exercise capacity and improves haemodynam
ics in patients with pulmonary hypertension, suggesting that endothelin has
an important role in pulmonary hypertension.